Search Page
Save citations to file
Email citations
Send citations to clipboard
Add to Collections
Add to My Bibliography
Create a file for external citation management software
Your saved search
Your RSS Feed
Filters
Results by year
Table representation of search results timeline featuring number of search results per year.
Year | Number of Results |
---|---|
2020 | 1 |
2022 | 1 |
2023 | 1 |
2024 | 4 |
Search Results
7 results
Results by year
Filters applied: . Clear all
It looks like you are searching for an author.
Results are currently sorted by Best Match. To see the newest results first,
change the sort order to Most Recent.
Page 1
Current barriers to initiating insulin therapy in individuals with type 2 diabetes.
Front Endocrinol (Lausanne). 2024 Mar 14;15:1366368. doi: 10.3389/fendo.2024.1366368. eCollection 2024.
Front Endocrinol (Lausanne). 2024.
PMID: 38559691
Free PMC article.
Review.
Prediabetes and Cardiometabolic Risk: The Need for Improved Diagnostic Strategies and Treatment to Prevent Diabetes and Cardiovascular Disease.
Lizarzaburu-Robles JC, Herman WH, Garro-Mendiola A, Galdón Sanz-Pastor A, Lorenzo O.
Lizarzaburu-Robles JC, et al. Among authors: galdon sanz pastor a.
Biomedicines. 2024 Feb 4;12(2):363. doi: 10.3390/biomedicines12020363.
Biomedicines. 2024.
PMID: 38397965
Free PMC article.
Review.
Item in Clipboard
Predictive Factors of Renal Function Decline in Patients with Type 2 Diabetes Treated with Canagliflozin in the Real-Wecan Study.
Gorgojo-Martinez JJ, Brito-Sanfiel M, Antón-Bravo T, Galdón Sanz-Pastor A, Wong-Cruz J, Gargallo Fernández MA.
Gorgojo-Martinez JJ, et al. Among authors: galdon sanz pastor a.
J Clin Med. 2022 Sep 24;11(19):5622. doi: 10.3390/jcm11195622.
J Clin Med. 2022.
PMID: 36233490
Free PMC article.
Item in Clipboard
Effectiveness and Tolerability of the Intensification of Canagliflozin Dose from 100 mg to 300 mg Daily in Patients with Type 2 Diabetes in Real Life: The INTENSIFY Study.
Gorgojo-Martinez JJ, Ferreira-Ocampo PJ, Galdón Sanz-Pastor A, Cárdenas-Salas J, Antón-Bravo T, Brito-Sanfiel M, Almodóvar-Ruiz F.
Gorgojo-Martinez JJ, et al. Among authors: galdon sanz pastor a.
J Clin Med. 2023 Jun 25;12(13):4248. doi: 10.3390/jcm12134248.
J Clin Med. 2023.
PMID: 37445283
Free PMC article.
Item in Clipboard
Endocrine Adverse Events Related To Immune Checkpoint Inhibitor Treatment: Relationship Between Antibodies and Severity of Thyroid Dysfunction.
Miguélez González M, Galdón Sanz-Pastor A, Áñez Gómez R, Brox Torrecilla N, Muñoz Moreno D, González Fernández L, Maricel Rivas A, López Guerra A, Álvarez R, Arranz JÁ, Márquez Rodas I, Escudero V, Sanjurjo M, Martín Vallejo J, Martín M, González Albarrán O.
Miguélez González M, et al. Among authors: galdon sanz pastor a.
Endocr Metab Immune Disord Drug Targets. 2024 Feb 14. doi: 10.2174/0118715303280679240206100137. Online ahead of print.
Endocr Metab Immune Disord Drug Targets. 2024.
PMID: 38362680
Item in Clipboard
Real-World Clinical Outcomes Associated with Canagliflozin in Patients with Type 2 Diabetes Mellitus in Spain: The Real-Wecan Study.
Gorgojo-Martínez JJ, Gargallo-Fernández MA, Galdón Sanz-Pastor A, Antón-Bravo T, Brito-Sanfiel M, Wong-Cruz J.
Gorgojo-Martínez JJ, et al. Among authors: galdon sanz pastor a.
J Clin Med. 2020 Jul 17;9(7):2275. doi: 10.3390/jcm9072275.
J Clin Med. 2020.
PMID: 32708943
Free PMC article.
Item in Clipboard
Are New Ultra-Rapid-Acting Insulins Associated with Improved Glycemic Control and Reduced Hypoglycemia in Comparison to Conventional Rapid-Acting Insulins for Individuals with Type 1 and Type 2 Diabetes? A Systematic Review and Meta-Analysis.
Villar-Taibo R, Galdón Sanz-Pastor A, Fernández-Rubio E, Barajas Galindo D, Simó Servat A, Ampudia-Blasco FJ.
Villar-Taibo R, et al. Among authors: galdon sanz pastor a.
Diabetes Technol Ther. 2024 Apr 15. doi: 10.1089/dia.2023.0524. Online ahead of print.
Diabetes Technol Ther. 2024.
PMID: 38502158
Item in Clipboard
Cite
Cite